Renoprotective effects of glp1r agonists and sglt2 inhibitors

New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The

renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial. Access through

your institution Buy or subscribe This is a preview of subscription content, access via your institution RELEVANT ARTICLES Open Access articles citing this article. * THE COMBINATION OF A

NEPRILYSIN INHIBITOR (SACUBITRIL) AND ANGIOTENSIN-II RECEPTOR BLOCKER (VALSARTAN) ATTENUATES GLOMERULAR AND TUBULAR INJURY IN THE ZUCKER OBESE RAT * Javad Habibi * , Annayya R. Aroor *  … 

Vincent G. DeMarco _Cardiovascular Diabetology_ Open Access 25 March 2019 * UP-TITRATION STRATEGY AFTER DPP-4 INHIBITOR-BASED ORAL THERAPY FOR TYPE 2 DIABETES: A RANDOMIZED CONTROLLED TRIAL

SHIFTING TO A SINGLE-DOSE GLP-1 ENHANCER VERSUS ADDING A VARIABLE BASAL INSULIN ALGORITHM * Masahiko Miyagi * , Hiroshi Uchino *  … Takahisa Hirose _Diabetes Therapy_ Open Access 18 August

2018 ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any

time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant

access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions *

Read our FAQs * Contact customer support REFERENCES * Muskiet, M. H. _ et al_. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. _Nat. Rev. Nephrol._ 13,

605–628 (2017). Article  CAS  Google Scholar  * DeFronzo, R. A. _ et al_. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. _Nat. Rev. Nephrol._ 13, 11–26 (2017).

Article  CAS  Google Scholar  * Mann, J. F. _ et al_. Liraglutide and renal outcomes in type 2 diabetes. _N. Engl. J. Med._ 377, 839–848 (2017). Article  CAS  Google Scholar  * Wanner, C. _

et al_. Empagliflozin and progression of kidney disease in type 2 diabetes. _N. Engl. J. Med._ 375, 323–334 (2016). Article  CAS  Google Scholar  * Marso, S. P. _ et al_. Liraglutide and

cardiovascular outcomes in type 2 diabetes. _N. Engl. J. Med._ 375, 311–322 (2016). Article  CAS  Google Scholar  * Zinman, B. _ et al_. Empagliflozin and cerebrovascular events in patients

with type 2 diabetes mellitus at high cardiovascular risk. _Stroke_ 48, 1218–1225 (2017). Article  CAS  Google Scholar  * Lewis, E. J. _ et al_. Renoprotective effect of the

angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. _N. Engl. J. Med._ 345, 12 (2001). Google Scholar  * Brenner, B. M. _ et al_. Effects of

losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. _N. Engl. J. Med._ 345, 12 (2001). Article  Google Scholar  * Hocher, B. Adenosine A1 receptor

antagonists in clinical research and development. _Kidney Int._ 78, 438–445 (2010). Article  CAS  Google Scholar  * Tsuprykov, O. _ et al_. The dipeptidyl peptidase inhibitor linagliptin

and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. _Kidney Int._ 89, 1049–1061 (2016). Article  CAS  Google Scholar 

Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal

University, Changsha, 410013, China Berthold Hocher * Institute of Nutritional Science, University of Potsdam, 14558, Nuthetal-Potsdam, Germany Oleg Tsuprykov Authors * Berthold Hocher View

author publications You can also search for this author inPubMed Google Scholar * Oleg Tsuprykov View author publications You can also search for this author inPubMed Google Scholar

CORRESPONDING AUTHOR Correspondence to Berthold Hocher. ETHICS DECLARATIONS COMPETING INTERESTS B.H. is a consultant for Boehringer Ingelheim on the development of dipeptidyl peptidase 4

(DPP4) inhibitors and has received research funding from this company for investigation of the renal effects of the DPP4 inhibitor linagliptin. O.T. declares no competing interests.

POWERPOINT SLIDES POWERPOINT SLIDE FOR TABLE 1 RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Hocher, B., Tsuprykov, O. Renoprotective effects of GLP1R

agonists and SGLT2 inhibitors. _Nat Rev Nephrol_ 13, 728–730 (2017). https://doi.org/10.1038/nrneph.2017.140 Download citation * Published: 09 October 2017 * Issue Date: December 2017 * DOI:

https://doi.org/10.1038/nrneph.2017.140 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative